Reportlinker Adds Castration Resistant Prostate Cancer: Clinical Insights From a US Oncologists' Survey
NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Castration Resistant Prostate Cancer: Clinical Insights from a US Oncologists' Survey
Progressively unfolding patient situation, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients.
This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US Oncologists on the treatment of patients with advanced prostate cancer.
Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists' decisions. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
• Understand what occurs with actual patients
• Access the most up-to-date prescribing trends
• Gain actionable data for developing and improving your market strategies
• Pinpoint needs of your target audience
• Focus resources to maximize the effectiveness of your budget
• Understand where your product fits
• Understand where your competitor's product fits
• Design messages to advance brand performance
Table of Contents
Executive Summary:5
Chapter 1: Introduction7
Table 1. Treatment Options in Advanced Prostate Cancer8
Chapter 2: Respondent Demographics9
Table 2.1 Eligibility Criteria for Survey Participation9
Figure 2.1 Gender of Survey Respondents9
Figure 2.2 Years Since Medical School Graduation10
Figure 2.3 Practice Settings10
Figure 2.4 Practices in NCI Cancer Centers11
Figure 2.5 Geographic Settings11
Figure 2.6 Survey Respondents by States12
Figure 2.7 Number of Physicians in Practice Groups13
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen13
Chapter 3: Elderly patient treated for Gleason's 7 adenocarcinoma, increased PSA 18 months later14
Figure 3.1 Barriers to optimal treatment14
Figure 3.2 Confidence in treating to optimal outcome16
Figure 3.3 Treatment following rising PSA on leuprolide17
Figure 3.4 Treatment decision upon disease progression18
Figure 3.5 Factors that influenced treatment20
Table 3.1 Factors that influenced treatment by types of agents selected21
Figure 3.6 Other agents that would be appropriate to include in therapy22
Figure 3.7 Treatment upon rising PSA23
Figure 3.8 Treatment upon further disease progression24
Chapter 4. Patient with Gleason's 3+4 adenocarcinoma and multiple metastases to pelvis and spine develops castration-resistant disease.26
Figure 4.1 Treatment Choices26
Figure 4.2 Confidence in treating to optimal outcome27
Figure 4.3 Cycles of docetaxel that the patient should receive28
Figure 4.4 Option to Continue LHRH agonist29
Figure 4.5 Factors Associated with Continuing LHRH Agonist29
Figure 4.6 Next Therapy with Good Performance Status upon Progressing after Docetaxel31
Chapter 5: Summary32
Appendix A: Survey Instrument33
Companies mentioned
Novartis, Astra Zeneca, Merck, Ferring, Abbott Laboratories, TEVA, Eli Lilly, Genentech/Roche, Bristol-Myers Squibb, Pfizer, Sanofi-aventis, Centocor/Ortho Biotech, EMD Serono, Dendreon, Celegene, Watson, Amgen
To order this report:
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article